Stockscreener 앱 받기
55.38
1.58%
-0.905
전일 마감가:
$56.29
열려 있는:
$56.26
하루 거래량:
520.44K
Relative Volume:
0.21
시가총액:
$10.64B
수익:
$2.95B
순이익/손실:
$523.88M
주가수익비율:
20.59
EPS:
2.69
순현금흐름:
$620.18M
1주 성능:
+5.40%
1개월 성능:
+1.69%
6개월 성능:
-3.74%
1년 성능:
-14.61%
1일 변동 폭
$54.80
$56.26
1주일 범위
$52.36
$56.45
52주 변동 폭
$50.76
$73.51
바이오마린 Stock (BMRN) Company Profile
명칭
Biomarin Pharmaceutical Inc
전화
(415) 506-6700
주소
105 DIGITAL DRIVE, NOVATO, CA
BMRN을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BMRN
Biomarin Pharmaceutical Inc
|
55.38 | 10.81B | 2.95B | 523.88M | 620.18M | 2.69 |
|
VRTX
Vertex Pharmaceuticals Inc
|
429.10 | 109.05B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
777.29 | 82.75B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
433.31 | 56.78B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
925.03 | 56.52B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
205.90 | 44.58B | 447.02M | -1.18B | -906.14M | -6.1812 |
바이오마린 Stock (BMRN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-11-06 | 다운그레이드 | Stifel | Buy → Hold |
| 2025-09-08 | 개시 | H.C. Wainwright | Neutral |
| 2025-09-03 | 개시 | Raymond James | Outperform |
| 2025-07-03 | 재개 | Morgan Stanley | Overweight |
| 2025-02-24 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2024-11-15 | 개시 | Wolfe Research | Outperform |
| 2024-10-30 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2024-10-10 | 재개 | Raymond James | Outperform |
| 2024-08-20 | 업그레이드 | Bernstein | Mkt Perform → Outperform |
| 2024-05-17 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2024-05-14 | 개시 | Evercore ISI | Outperform |
| 2023-11-15 | 개시 | Wells Fargo | Overweight |
| 2023-10-23 | 업그레이드 | Bernstein | Underperform → Mkt Perform |
| 2023-09-28 | 개시 | Raymond James | Mkt Perform |
| 2023-09-18 | 개시 | UBS | Buy |
| 2023-07-27 | 개시 | Scotiabank | Sector Perform |
| 2023-07-05 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2023-06-14 | 재개 | Credit Suisse | Outperform |
| 2023-03-21 | 개시 | Bernstein | Underperform |
| 2023-02-22 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2023-02-21 | 개시 | Citigroup | Neutral |
| 2023-01-30 | 개시 | BMO Capital Markets | Market Perform |
| 2023-01-18 | 개시 | Canaccord Genuity | Hold |
| 2022-10-31 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2022-07-13 | 개시 | Cantor Fitzgerald | Overweight |
| 2022-06-13 | 재개 | Wedbush | Neutral |
| 2022-04-25 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2021-11-22 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2021-10-07 | 재개 | Jefferies | Buy |
| 2021-09-09 | 업그레이드 | Stifel | Hold → Buy |
| 2021-06-04 | 재개 | Robert W. Baird | Outperform |
| 2021-04-26 | 재개 | Credit Suisse | Outperform |
| 2021-03-04 | 재개 | Guggenheim | Buy |
| 2021-03-01 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2020-08-20 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2020-08-20 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2020-08-19 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2020-08-19 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-08-19 | 다운그레이드 | Stifel | Buy → Hold |
| 2020-07-08 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2020-07-06 | 재확인 | Citigroup | Buy |
| 2020-01-28 | 개시 | BMO Capital Markets | Market Perform |
| 2020-01-27 | 개시 | BMO Capital Markets | Market Perform |
| 2020-01-24 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2019-11-27 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2019-11-12 | 개시 | SunTrust | Buy |
| 2019-10-17 | 재개 | BofA/Merrill | Buy |
| 2019-05-23 | 재개 | Citigroup | Buy |
| 2019-04-09 | 재개 | Raymond James | Outperform |
| 2019-01-02 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2018-12-14 | 개시 | Wolfe Research | Outperform |
| 2018-10-01 | 개시 | Cantor Fitzgerald | Overweight |
| 2018-08-07 | 재확인 | Stifel | Buy |
| 2018-08-03 | 재확인 | Stifel | Buy |
모두보기
바이오마린 주식(BMRN)의 최신 뉴스
Q3 Earnings Outperformers: BioMarin Pharmaceutical (NASDAQ:BMRN) And The Rest Of The Therapeutics Stocks - Finviz
AbbVie, Biogen, BioMarin Pharmaceutical, DexCom, and Abbott Laboratories Stocks Trade Up, What You Need To Know - Finviz
Will BioMarin Pharmaceutical Inc. (BM8) stock beat revenue estimatesWeekly Trend Summary & Comprehensive Market Scan Insights - newser.com
How BioMarin Pharmaceutical Inc. (BM8) stock responds to bond marketTrade Exit Report & Weekly High Conviction Trade Ideas - newser.com
Will BioMarin Pharmaceutical Inc. (BM8) stock outperform global peersMarket Sentiment Review & Entry Point Confirmation Signals - newser.com
BioMarin Offers to Buy Inozyme for $270M to Boost Enzyme Therapy Biz - MSN
Will BioMarin Pharmaceutical Inc. (BM8) stock attract long term capital inflowsJuly 2025 Technicals & Verified Momentum Stock Watchlist - newser.com
Is BioMarin Pharmaceutical Inc. (BM8) stock cheap vs fundamentalsCEO Change & AI Enhanced Market Trend Forecasts - newser.com
How higher bond yields impact BioMarin Pharmaceutical Inc. (BM8) stock2025 Fundamental Recap & Fast Gain Swing Trade Alerts - newser.com
Will BioMarin Pharmaceutical Inc. (BM8) stock hit analyst forecasts2025 Key Lessons & Fast Gain Stock Tips - newser.com
BioMarin Pharmaceutical (BMRN): Buy, Sell, or Hold Post Q3 Earnings? - Finviz
Will BioMarin Pharmaceutical Inc. stock split attract more investors - newser.com
Key resistance and support levels for BioMarin Pharmaceutical Inc.CEO Change & Consistent Profit Trade Alerts - newser.com
Is BioMarin Pharmaceutical Inc. (BM8) stock undervalued historicallyQuarterly Market Summary & Daily Stock Trend Watchlist - newser.com
What momentum indicators show for BioMarin Pharmaceutical Inc. stock2025 Price Action Summary & Weekly Stock Performance Updates - newser.com
How strong is BioMarin Pharmaceutical Inc. stock balance sheetJuly 2025 Momentum & Weekly Breakout Stock Alerts - newser.com
Why BioMarin Pharmaceutical Inc. stock is seen as undervaluedJobs Report & Risk Controlled Swing Alerts - newser.com
Biomarin Pharmaceutical Inc (BM8.HA) Stock Price, News, Quote & History - Yahoo! Finance Canada
How currency fluctuations impact BioMarin Pharmaceutical Inc. stockJuly 2025 EndofMonth & Real-Time Sentiment Analysis - newser.com
바이오마린 (BMRN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.23%
1.11%
자본화:
|
볼륨(24시간):